Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Veronika ZimolovaLaboratory of Cell and Developmental Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
Monika BurocziovaLaboratory of Hematooncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
Linda BerkovaLaboratory of Cell and Developmental Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
Srdjan GrusanovicLaboratory of Hematooncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
Jan GurskyDepartment of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
Lubos JanotkaDepartment of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.ORCID 0009-0005-4400-3654
Petr KasparekCzech Centre for Phenogenomics & Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
Alena PecinovaLaboratory of Bioenergetics, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0002-0204-7502
David KundratDepartment of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.ORCID 0000-0003-4770-1229
Dusan HrckulakLaboratory of Cell and Developmental Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0002-1752-3612
Jakub OnhajzerLaboratory of Cell and Developmental Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0001-6569-6836
Ivana JeziskovaDepartment of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University and ERN EuroBloodNet Centre, Brno, Czech Republic.
Barbora WeinbergerovaDepartment of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University and ERN EuroBloodNet Centre, Brno, Czech Republic.ORCID 0000-0001-6460-2471
Sarka PospisilovaDepartment of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University and ERN EuroBloodNet Centre, Brno, Czech Republic.ORCID 0000-0001-7136-2680
Michael DoubekDepartment of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University and ERN EuroBloodNet Centre, Brno, Czech Republic.ORCID 0000-0002-1269-6282
Meritxell Alberich-JordaLaboratory of Hematooncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
Vladimir KorinekLaboratory of Cell and Developmental Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
Vladimir Divoky *Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. vladimir.divoky@upol.cz.ORCID 0000-0003-0202-245X
Lucie Lanikova *Laboratory of Cell and Developmental Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic. lucie.lanikova@img.cas.cz.ORCID 0000-0002-2845-8692
Funding
Agentura Pro Zdravotnický Výzkum České Republiky (Czech Health Research Council) NU21/03/00338Grantová Agentura České Republiky (Grant Agency of the Czech Republic) 24-11730SMinisterstvo Školství, Mládeže a Tělovýchovy (Ministry of Education, Youth and Sports) CZ.02.1.01/0.0/0.0/16_026/0008448Ministerstvo Školství, Mládeže a Tělovýchovy (Ministry of Education, Youth and Sports) CZ.02.1.01/0.0/0.0/18_046/0015861Ministerstvo Školství, Mládeže a Tělovýchovy (Ministry of Education, Youth and Sports) LM 2018126Ministerstvo Školství, Mládeže a Tělovýchovy (Ministry of Education, Youth and Sports) LM2023067Ministerstvo Zdravotnictví Ceské Republiky (Ministry of Health of the Czech Republic) FNBr 65269705
6 · The paper itself
Abstract
The acquired JAK2-V617F mutation plays a causal role in myeloproliferative neoplasms (MPN). Weakly activating JAK2 germline variants have been associated with MPN risk, but the underlying mechanisms remain unclear. We previously identified the JAK2-R1063H germline variant, which contributes to hereditary MPN and increased disease severity in essential thrombocythemia. Here, we studied alterations in hematopoiesis in Jak2-R1063H knock-in mice. The Jak2-R1063H mouse cohort exhibited increased mortality, stimulated thrombopoiesis and elevated D-dimers levels, indicative of thrombotic complications. Bone marrow analysis revealed myeloid bias, enhanced megakaryopoiesis and activation of inflammatory signaling. Transcriptional and functional assays of hematopoietic stem cells suggested their accelerated aging and functional decline. The Egr1 transcriptional network, including the Thbs1 gene, progressively increased in aging mice, reinforcing alterations initiated by Jak2/Stat signaling. In murine acute myelogenous leukemia models, the Jak2-R1063H cooperated with a driver oncogene in promoting leukemogenesis. Germline JAK2-R1063H was found in 10 of 200 MPN patients from local hematology centers, with a higher minor allele frequency compared to healthy controls. Patients harboring JAK2-R1063H variant exhibited an increased incidence of thrombotic complications and disease progression with shortened survival. In conclusion, our findings identify the JAK2-R1063H germline variant as a risk factor for MPN development, thrombotic complications, and leukemic transformation. Our study, which involves a mouse model and a cohort of 200 MPN patients, characterizes the JAK2-R1063H germline mutation as a risk factor for MPN development, thrombotic complications, and leukemic transformation. These findings may have important clinical implications for managing MPN patients carrying the JAK2-R1063H germline variant.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation. · full record | OpenQuestion